skip to Main Content

Utilizing Liquid Biopsy to Diagnose Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Researchers from the Mayo Clinic and other institutions conducted a study to determine the feasibility and efficacy of circulating tumor DNA (ctDNA) profiling for the diagnosis of pancreatic ductal adenocarcinoma (PDAC).

CtDNA profiling is a non-invasive liquid biopsy method that measures DNA fragments from cancer cells that have been released into the bloodstream. PDAC is typically diagnosed using results from an endoscopic ultrasound or endoscopic retrograde cholangiopancreatography. Read more . . . 

Back To Top